Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions
Head & Neck · 2026-09 · 48 (9) · 2584-2592
DOI: 10.1002/hed.70385 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Head & Neck, online erschienen am 09.07.2026. Verfasst von Carol R Bradford und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Immunotherapy, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.
Methods
This review summarizes pivotal clinical trials evaluating immunotherapeutic strategies in HNSCC, including PD‐1/PD‐L1 inhibitors, combination regimens, and emerging modalities across recurrent/metastatic and curative‐intent settings, with attention to efficacy, safety, and biomarkers.
Results
Phase III trials have established pembrolizumab and nivolumab as standards of care in recurrent or metastatic HNSCC, demonstrating improved overall survival and favorable toxicity profiles. Recent studies support earlier integration of immunotherapy, including neoadjuvant and adjuvant approaches, with meaningful gains in event‐free and disease‐free survival.
Conclusions
Immunotherapy is reshaping the management of HNSCC. Ongoing trials, biomarker refinement, and novel strategies are expected to further expand benefit and personalize treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Sri Shankara Cancer Hospital and Research Centre, Bangalore, India.
- Head and Neck Surgical Oncology Department, Sri Shankara Cancer Hospital and Research Centre, Bangalore, India.
- ENT Department, Jena University Hospital, Jena, Germany.
- Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
- International Head and Neck Scientific Group, Padua, Italy.
ORCID-Profile: Carol R Bradford, Sreeram M P, Karthik N Rao, Orlando Guntinas-Lichius, Nabil Saba
Zitieren
APA
Bradford, C. R., M P, S., Rao, K. N., Guntinas-Lichius, O., Saba, N., & Ferlito, A. (2026). Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions. Head & Neck, 48(9), 2584-2592. https://doi.org/10.1002/hed.70385
Vancouver
Bradford CR, M P S, Rao KN, Guntinas-Lichius O, Saba N, Ferlito A. Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions. Head & Neck. 2026;48(9):2584-2592. doi:10.1002/hed.70385
BibTeX
@article{Bradford2026,
author = {Bradford, Carol R and M P, Sreeram and Rao, Karthik N and Guntinas-Lichius, Orlando and Saba, Nabil and Ferlito, Alfio},
title = {Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions},
journal = {Head & Neck},
year = {2026},
volume = {48},
number = {9},
pages = {2584--2592},
doi = {10.1002/hed.70385}
}
EUVIMED